Prescription attached:-

đ§ LIPU MED â FULL CLINICAL CASE REVIEW
Prescription Analysis | Clinical Working Diagnosis | MedEx Drug Review | Evidence-Based ENT Assessment
Proposed Website Publication Title:
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻĒāϰā§āĻĻāĻž āĻāϞā§āϞā§āĻāϝā§āĻā§āϝāĻāĻžāĻŦā§ āĻŦāĻžāĻŽ āĻĻāĻŋāĻā§ āĻŦāĻžāĻāĻāĻž (Gross Left-Sided DNS), āϝāĻžāϰ āϏāĻā§āĻā§ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āύāĻžāĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš (Allergic Rhinitis) āĻĨāĻžāĻāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϰā§ā§āĻā§āĨ¤
Attachments: 1 Prescription + 0 Investigation Reports + 0 Clinical Images
Overall diagnostic confidence: 0.86 for documented DNS; 0.65 for associated allergic rhinitis.
Clinical verification note: āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϞā§āĻāĻž āϤāĻĨā§āϝ, āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ āĻāĻŦāĻ āĻāĻŽāĻžāϰ clinical inference āĻāϞāĻžāĻĻāĻžāĻāĻžāĻŦā§ āĻāĻĒāϏā§āĻĨāĻžāĻĒāύ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤ āϰā§āĻā§āĻā§ āĻĒāϰā§āĻā§āώāĻž āĻāϰāĻž āĻšā§āύāĻŋ āĻāĻŦāĻ āĻā§āύ⧠investigation report āĻĻā§āĻā§āĻž āĻšā§āύāĻŋāĨ¤ āϤāĻžāĻ Allergic Rhinitis āϏāĻŽā§āĻāĻžāĻŦā§āϝ diagnosis, āύāĻŋāĻļā§āĻāĻŋāϤ diagnosis āύā§āĨ¤ āĻ āϏā§āĻĒāώā§āĻ āĻšāĻžāϤā§āϰ āϞā§āĻāĻž āĻ āύā§āĻŽāĻžāύ āĻāϰ⧠āύāĻŋāĻļā§āĻāĻŋāϤ āϤāĻĨā§āϝ āĻšāĻŋāϏā§āĻŦā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻšā§āύāĻŋāĨ¤
đŠ 01. Website-Verified Case Number | āĻā§ā§āĻŦāϏāĻžāĻāĻ āϝāĻžāĻāĻžāĻāĻā§āϤ āĻā§āϏ āύāĻŽā§āĻŦāϰ
ā§¨ā§Ž āĻ āĻā§āĻā§āĻŦāϰ ⧍ā§Ļ⧍ā§Ŧ āϤāĻžāϰāĻŋāĻā§ raiyyantahsan.com Blog āϝāĻžāĻāĻžāĻ āĻāϰ⧠āĻĒāĻžāĻā§āĻž āϏāϰā§āĻŦāĻļā§āώ āĻĒā§āϰāĻāĻžāĻļāĻŋāϤ āĻā§āϏ:
TC(1448).(01). Cardiology Department Case No (50)
āĻĒā§āϰāĻāĻžāĻļā§āϰ āϤāĻžāϰāĻŋāĻ: 28 October 2026āĨ¤
ENT āĻŦāĻŋāĻāĻžāĻā§āϰ āϏāϰā§āĻŦāĻļā§āώ āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤ āĻā§āϏ:
TC(1437).(12). ENT Department Case No (102)
āĻĒā§āϰāĻāĻžāĻļā§āϰ āϤāĻžāϰāĻŋāĻ: 26 October 2026āĨ¤
āϏā§āĻ āĻ āύā§āϝāĻžā§ā§ āĻāĻ āύāϤā§āύ āĻā§āϏā§āϰ āĻĒā§āϰāϏā§āϤāĻžāĻŦāĻŋāϤ āύāĻŽā§āĻŦāϰ:
TC(1449).(12). ENT Department Case No (103)
āĻāĻāĻŋ āĻā§ā§āĻŦāϏāĻžāĻāĻā§āϰ āĻĻā§āĻļā§āϝāĻŽāĻžāύ numbering sequence āĻ āύā§āϝāĻžā§ā§ āϤā§āϰāĻŋ āĻĒāϰāĻŦāϰā§āϤ⧠āύāĻŽā§āĻŦāϰ; āύāϤā§āύ āĻā§āϏāĻāĻŋ āĻāĻāύ⧠āĻĒā§āϰāĻāĻžāĻļāĻŋāϤ āĻŦāĻž āϏāĻāϰāĻā§āώāĻŋāϤ āύā§āĨ¤
Confidence: 0.97
đ§ 02. Patient Information | āϰā§āĻā§āϰ āϤāĻĨā§āϝ
| Parameter | Prescription Findings | Confidence |
|---|---|---|
| Patient Name â āϰā§āĻā§āϰ āύāĻžāĻŽ | āĻā§āĻĒāύā§ā§āϤāĻžāϰ āĻāύā§āϝ āĻĒā§āϰāĻāĻžāĻļ āĻāϰāĻž āĻšā§āύāĻŋ | 1.00 |
| Age â āĻŦā§āϏ | 32 years | 0.98 |
| Sex â āϞāĻŋāĻā§āĻ | Male â āĻĒā§āϰā§āώ; āύāĻžāĻŽā§āϰ āĻāĻā§ Mr. āϞā§āĻāĻž | 0.95 |
| Prescription Date | 09 October 2026 | 0.95 |
| Department | ENT â āύāĻžāĻ, āĻāĻžāύ āĻ āĻāϞāĻž āĻŦāĻŋāĻāĻžāĻ | 1.00 |
| Consultant | Dr. Ratan Bikash Rudra | 0.99 |
| Specialty | ENT Specialist & Surgeon | 0.99 |
| Reports Available | None â āĻā§āύ⧠āϰāĻŋāĻĒā§āϰā§āĻ āϏāĻāϝā§āĻā§āϤ āύā§āĻ | 1.00 |
đŠ 03. C/C â Chief Complaints | āĻĒā§āϰāϧāĻžāύ āĻāĻĒāϏāϰā§āĻ
Doctor’s Documentation
C/C: Not documented â āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻĒā§āϰāϧāĻžāύ āĻāĻĒāϏāϰā§āĻ āϞā§āĻāĻž āύā§āĻāĨ¤
Confidence: 0.99
Clinically Inferred Complaints | āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻĒāϏāϰā§āĻ
āĻāώā§āϧā§āϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻŦāĻ Gross DNS (Lt) āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻĒāϏāϰā§āĻāĻā§āϞā§:
| Suspected C/C | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Confidence |
|---|---|---|
| Nasal obstruction | āύāĻžāĻ āĻŦāύā§āϧ āĻĨāĻžāĻāĻž āĻŦāĻž āĻļā§āĻŦāĻžāϏ āύāĻŋāϤ⧠āĻŦāĻžāϧāĻž | 0.85 |
| Predominantly left-sided nasal blockage | āĻŦāĻžāĻŽ āύāĻžāĻā§ āϤā§āϞāύāĻžāĻŽā§āϞāĻ āĻŦā§āĻļāĻŋ āĻŦāĻžāϧāĻž | 0.70 |
| Nasal congestion | āύāĻžāĻā§āϰ āĻā§āϤāϰā§āϰ āĻāĻŦāϰāĻŖ āĻĢā§āϞ⧠āύāĻžāĻ āĻŦāύā§āϧ āĻšāĻā§āĻž | 0.85 |
| Sneezing | āĻšāĻžāĻāĻāĻŋ | 0.55 |
| Rhinorrhoea | āύāĻžāĻ āĻĻāĻŋā§ā§ āĻĒāĻžāύāĻŋ āĻĒā§āĻž | 0.55 |
| Nasal itching | āύāĻžāĻ āĻā§āϞāĻāĻžāύ⧠| 0.50 |
Clinical interpretation â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻŦā§āϝāĻžāĻā§āϝāĻž:
Gross DNS-āĻāϰ āĻāĻžāϰāĻŖā§ āύāĻžāĻā§āϰ āĻā§āϤāϰā§āϰ āĻŦāĻžā§ā§ āĻāϞāĻžāĻāϞā§āϰ āĻĒāĻĨ āϏāĻāĻā§āĻāĻŋāϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ āĻ āύā§āϝāĻĻāĻŋāĻā§ Bilastine āĻ Montelukast āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻžāϰāĻŖā§ āĻāĻŋāĻāĻŋā§āϏāĻ allergic symptoms āύāĻŋā§āύā§āϤā§āϰāĻŖā§āϰ āĻā§āώā§āĻāĻž āĻāϰāĻā§āύ āĻŦāϞ⧠āĻŽāύ⧠āĻšā§āĨ¤
āϤāĻŦā§ āĻāώā§āϧ āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§ āĻŦāϞā§āĻ āϰā§āĻā§āϰ āĻšāĻžāĻāĻāĻŋ, āύāĻžāĻ āĻā§āϞāĻāĻžāύ⧠āĻŦāĻž āύāĻžāĻ āĻĻāĻŋā§ā§ āĻĒāĻžāύāĻŋ āĻĒā§āĻžāϰ āĻāϤāĻŋāĻšāĻžāϏ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤
đ§ 04. History Assessment | āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āύāĻŋāĻā§āϰ history-āϏāĻāĻā§āϰāĻžāύā§āϤ āĻā§āώā§āϤā§āϰāĻā§āϞā§āϰ āĻā§āύ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϤāĻĨā§āϝ āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋāĨ¤
| History | English Meaning | āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž | Documentation |
|---|---|---|---|
| I/H â Illness History | Present illness history | āĻŦāϰā§āϤāĻŽāĻžāύ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
| O/H â Occupational History | Occupational exposure | āĻĒā§āĻļāĻžāĻāϤ āĻāϤāĻŋāĻšāĻžāϏ, āϧā§āϞāĻžāĻŦāĻžāϞāĻŋ āĻŦāĻž āϰāĻžāϏāĻžā§āύāĻŋāĻā§āϰ āϏāĻāϏā§āĻĒāϰā§āĻļ | Not documented |
| D/H â Drug History | Previous/current medicine use | āĻāĻā§ āĻŦāĻž āĻŦāϰā§āϤāĻŽāĻžāύ⧠āĻŦā§āϝāĻŦāĻšā§āϤ āĻāώā§āϧā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
| M/H â Medical History | Past or existing diseases | āĻĒā§āϰā§āĻŦā§āϰ āĻ āĻŦāϰā§āϤāĻŽāĻžāύ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
| S/H â Surgical History | Previous operations | āĻāĻā§āϰ āĻ āϏā§āϤā§āϰā§āĻĒāĻāĻžāϰā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
| F/H â Family History | Familial disease history | āĻĒāĻžāϰāĻŋāĻŦāĻžāϰāĻŋāĻ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
| A/H â Allergy History | Drug/environmental allergy | āĻāώā§āϧ āĻŦāĻž āĻĒāϰāĻŋāĻŦā§āĻļāĻāϤ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented |
| O/S/E â Other Systemic Examination | Assessment of other body systems | āĻ āύā§āϝāĻžāύā§āϝ āĻ āĻā§āĻāϤāύā§āϤā§āϰ āĻĒāϰā§āĻā§āώāĻž | Not documented |
| O/G/E â Overall General Examination | General physical examination | āϏāĻžāĻŽāĻā§āϰāĻŋāĻ āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž | Not documented |
Confidence: 0.99
Important History to Obtain | āϝ⧠āĻāϤāĻŋāĻšāĻžāϏ āĻāĻžāύāĻž āĻĒā§āϰā§ā§āĻāύ
āĻāĻ āϰā§āĻā§āϰ āϏāĻ āĻŋāĻ clinical assessment āĻāϰāϤ⧠āĻāĻžāύāϤ⧠āĻšāĻŦā§:
- āύāĻžāĻ āĻŦāύā§āϧ āĻāϤāĻĻāĻŋāύ āϧāϰā§?
- āĻŦāĻžāĻŽ āύāĻžāĻ āĻŦā§āĻļāĻŋ āĻŦāύā§āϧ āĻĨāĻžāĻā§, āύāĻžāĻāĻŋ āĻĻā§āĻ āύāĻžāĻāĻ?
- āĻšāĻžāĻāĻāĻŋ, āύāĻžāĻ āĻā§āϞāĻāĻžāύāĻŋ, āύāĻžāĻ āĻĻāĻŋā§ā§ āĻĒāĻžāύāĻŋ āĻĒā§āĻž āĻāĻā§ āĻāĻŋ?
- āϰāĻžāϤ⧠āύāĻžāĻ āĻŦāύā§āϧ, āĻŽā§āĻ āĻĻāĻŋā§ā§ āĻļā§āĻŦāĻžāϏ āύā§āĻā§āĻž āĻŦāĻž āύāĻžāĻ āĻĄāĻžāĻāĻžāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāĻā§ āĻāĻŋ?
- āĻāĻā§ āύāĻžāĻā§ āĻāĻāĻžāϤ āĻĒā§ā§ā§āĻāĻŋāϞā§āύ āĻāĻŋ?
- āĻāĻā§ nasal spray āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāĻā§ āĻāĻŋ?
- Asthma, hypertension, glaucoma āĻŦāĻž psychiatric illness āĻāĻā§ āĻāĻŋ?
Confidence: 0.95 â āĻāĻā§āϞ⧠āĻĒā§āϰā§ā§āĻāύā§ā§ history questions, āϰā§āĻā§āϰ āύāĻĨāĻŋāĻā§āĻā§āϤ history āύā§āĨ¤
đŠ 05. O/E â On Examination | āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž
Documented Finding
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ Advice āĻ āĻāĻļā§ āϞā§āĻāĻž:
Gross DNS (Lt)
āĻāϰ āĻĒā§āϰā§āĻŖāϰā§āĻĒ:
Gross Deviated Nasal Septum â Left Side
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻŽāϧā§āϝāĻŦāϰā§āϤ⧠āĻĒāϰā§āĻĻāĻž āĻāϞā§āϞā§āĻāϝā§āĻā§āϝāĻāĻžāĻŦā§ āĻŦāĻžāĻŽ āĻĻāĻŋāĻā§ āĻŦāĻžāĻāĻāĻžāĨ¤
āĻāĻāĻŋ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āύāĻĨāĻŋāĻā§āĻā§āϤ āĻĒā§āϰāϧāĻžāύ anatomical findingāĨ¤
Confidence: 0.98
O/E āĻ āĻāĻļā§ āĻāϰāĻ āĻā§āĻ āĻāĻāĻāĻŋ āĻ āϏā§āĻĒāώā§āĻ āϞā§āĻāĻž āϰā§ā§āĻā§āĨ¤ āϏā§āĻāĻŋ āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝāĻāĻžāĻŦā§ āĻĒāĻžāĻ ā§āĻĻā§āϧāĻžāϰ āĻāϰāĻž āϏāĻŽā§āĻāĻŦ āĻšā§āύāĻŋāĨ¤
Clinical Meaning
Nasal Septum: āύāĻžāĻā§āϰ āĻĻā§āĻ āĻĒāĻžāĻļāĻā§ āĻĒā§āĻĨāĻ āĻāϰ⧠āĻāĻŽāύ cartilage āĻ bone āĻĻā§āĻŦāĻžāϰāĻž āĻāĻ āĻŋāϤ āĻĒāϰā§āĻĻāĻžāĨ¤
Septal Deviation: āĻāĻ āĻĒāϰā§āĻĻāĻž āĻŽāĻžāĻā§āϰ āĻ āĻŦāϏā§āĻĨāĻžāύ āĻĨā§āĻā§ āĻāĻāĻĻāĻŋāĻā§ āϏāϰ⧠āĻŦāĻž āĻŦāĻžāĻāĻāĻž āĻšā§ā§ āĻĨāĻžāĻāĻžāĨ¤
Gross DNS: āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻŦāϰā§āĻŖāύāĻžā§ āĻāϞā§āϞā§āĻāϝā§āĻā§āϝ āĻŽāĻžāϤā§āϰāĻžāϰ septal deviationāĨ¤
āĻāĻāĻŋ āύāĻžāĻā§āϰ āĻŦāĻžā§ā§ āĻāϞāĻžāĻāϞ⧠āĻŦāĻžāϧāĻž āϏā§āώā§āĻāĻŋ āĻāϰāϤ⧠āĻĒāĻžāϰā§āĨ¤ āϤāĻŦā§ āĻļā§āϧ⧠anatomical deviation āĻĻā§āĻā§ āĻāĻĒāϏāϰā§āĻā§āϰ āϤā§āĻŦā§āϰāϤāĻž āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤
đ§ 06. Investigations | āĻāĻŋāĻāĻŋā§āϏāĻ āϝ⧠āĻĒāϰā§āĻā§āώāĻžāĻā§āϞ⧠āĻĻāĻŋā§ā§āĻā§āύ
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ Advice āĻ āĻāĻļā§ āύāĻŋāĻā§āϰ āĻĒāϰā§āĻā§āώāĻžāĻā§āϞ⧠āĻĒā§āĻž āϝāĻžāĻā§āĻā§āĨ¤
| No. | Investigation | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Clinical Purpose | Confidence |
|---|---|---|---|---|
| 1 | CBC | Complete Blood Count â āϏāĻŽā§āĻĒā§āϰā§āĻŖ āϰāĻā§āϤāĻāĻŖāĻŋāĻāĻž āĻĒāϰā§āĻā§āώāĻž | Anaemia, platelet count āĻ āĻ āύā§āϝāĻžāύā§āϝ haematological abnormalities āĻŽā§āϞā§āϝāĻžā§āύ | 0.99 |
| 2 | BT | Bleeding Time â āϰāĻā§āϤāĻĒāĻžāϤ āĻŦāύā§āϧ āĻšāϤ⧠āϞāĻžāĻāĻž āϏāĻŽā§ | āĻāϤāĻŋāĻšāĻžāϏāĻŋāĻ bleeding assessment | 0.99 |
| 3 | CT | Clotting Time â āϰāĻā§āϤ āĻāĻŽāĻžāĻ āĻŦāĻžāĻāϧāĻžāϰ āϏāĻŽā§ | āĻāϤāĻŋāĻšāĻžāϏāĻŋāĻ clotting assessment | 0.99 |
| 4 | Blood Urea | āϰāĻā§āϤ⧠āĻāĻāϰāĻŋā§āĻžāϰ āĻĒāϰāĻŋāĻŽāĻžāĻŖ | Renal assessment â āĻāĻŋāĻĄāύāĻŋ āĻŽā§āϞā§āϝāĻžā§āύ | 0.98 |
| 5 | RBS | Random Blood Sugar â āϝā§āĻā§āύ⧠āϏāĻŽā§ā§ āϰāĻā§āϤā§āϰ āĻā§āϞā§āĻā§āĻ | Hyperglycaemia āĻŦāĻž diabetes screening | 0.99 |
| 6 | ECG | Electrocardiogram â āĻšā§āĻĻā§âāϝāύā§āϤā§āϰā§āϰ āĻŦā§āĻĻā§āϝā§āϤāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž | Cardiac assessment | 0.99 |
| 7 | X-ray Chest PA | āĻŦā§āĻā§āϰ āĻāĻā§āϏ-āϰ⧠| Selected cardiopulmonary assessment | 0.98 |
| 8 | X-ray PNS â OM View | Paranasal Sinuses X-ray, Occipitomental View â āϏāĻžāĻāύāĻžāϏā§āϰ āĻāĻā§āϏ-āϰ⧠| āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ sinus pathology āĻŽā§āϞā§āϝāĻžā§āύ | 0.96 |
| 9 | Blood Group | āϰāĻā§āϤā§āϰ āĻā§āϰā§āĻĒ āύāĻŋāϰā§āĻŖā§ | āĻĒā§āϰā§ā§āĻāύ⧠operative planning | 0.99 |
| 10 | HBsAg | Hepatitis B Surface Antigen â āĻšā§āĻĒāĻžāĻāĻžāĻāĻāĻŋāϏ āĻŦāĻŋ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻŋāĻšā§āύ | HBV screening | 0.98 |
Important clarification â āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻŦā§āϝāĻžāĻā§āϝāĻž:
āĻāĻ āĻĒāϰā§āĻā§āώāĻžāĻā§āϞā§āϰ āϤāĻžāϞāĻŋāĻāĻž āĻĻā§āĻā§ preoperative assessment-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϤā§āϰāĻŋ āĻšā§āĨ¤ āĻ āϰā§āĻĨāĻžā§ āĻāĻŋāĻāĻŋā§āϏāĻ Septoplasty āĻŦāĻž āĻ āύā§āϝ āĻā§āύ⧠ENT procedure āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰ⧠āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
āĻāĻŋāύā§āϤ⧠āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϏā§āĻĒāώā§āĻāĻāĻžāĻŦā§ āĻ āϏā§āϤā§āϰā§āĻĒāĻāĻžāϰā§āϰ āύāĻŋāϰā§āĻĻā§āĻļ āϞā§āĻāĻž āύā§āĻāĨ¤
Preoperative assessment inference confidence: 0.75.
Are all these investigations necessary?
āϏāĻŦ āĻĒāϰā§āĻā§āώāĻž āĻĒā§āϰāϤā§āϝā§āĻ DNS āϰā§āĻā§āϰ āĻāύā§āϝ āĻŦāĻžāϧā§āϝāϤāĻžāĻŽā§āϞāĻ āύā§āĨ¤
NICE NG45 āĻ āύā§āϝāĻžā§ā§ elective surgery-āĻāϰ āĻāĻā§ ECG, chest X-ray, coagulation test āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ āĻĒāϰā§āĻā§āώāĻž āϰā§āĻā§āϰ āĻļāĻžāϰā§āϰāĻŋāĻ āĻ āĻŦāϏā§āĻĨāĻž, āϏāĻšāϰā§āĻ āĻ āĻ āϏā§āϤā§āϰā§āĻĒāĻāĻžāϰā§āϰ āĻā§āĻāĻāĻŋ āĻ āύā§āϝāĻžā§ā§ āύāĻŋāϰā§āĻŦāĻžāĻāύ āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
āĻŦāĻŋāĻļā§āώāϤ:
- BT/CT: āĻāϧā§āύāĻŋāĻ preoperative bleeding-risk assessment-āĻāϰ āĻāύā§āϝ āϏāĻžāϧāĻžāϰāĻŖāϤ āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝ screening test āύā§āĨ¤
- Chest X-ray: āϏā§āϏā§āĻĨ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āύāĻŋā§āĻŽāĻŋāϤ āĻāϰāĻž āϏā§āĻĒāĻžāϰāĻŋāĻļ āĻāϰāĻž āĻšā§ āύāĻžāĨ¤
- ECG: āĻŦā§āϏ, cardiovascular history āĻ operative risk āĻŦāĻŋāĻŦā§āĻāύāĻžā§ āĻĒā§āϰā§ā§āĻāύ āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāĻž āĻšā§āĨ¤
- X-ray PNS: DNS āύāĻŋāϰā§āĻŖā§ā§āϰ āĻāύā§āϝ āĻ āĻĒāϰāĻŋāĻšāĻžāϰā§āϝ āύā§; sinus disease āϏāύā§āĻĻā§āĻš āĻšāϞ⧠āĻāĻĒāϝā§āĻā§āϤ āĻŽā§āϞā§āϝāĻžā§āύ āĻĒā§āϰā§ā§āĻāύāĨ¤
āĻāĻā§āϞ⧠āĻŦāϰā§āϤāĻŽāĻžāύ guideline āĻ āύā§āϝāĻžā§ā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻŦāĻŋāώā§āĨ¤
Confidence: 0.96
đŠ 07. Doctor’s Diagnosis | āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϰā§āĻāύāĻŋāϰā§āĻŖā§
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāϞāĻžāĻĻāĻž Dx āĻāϰ āĻĒā§āϰāĻŖ āĻāϰāĻž āĻšā§āύāĻŋāĨ¤
āϤāĻŦā§ Advice āĻ āĻāĻļā§ āϏā§āĻĒāώā§āĻāĻāĻžāĻŦā§ āϞā§āĻāĻž āϰā§ā§āĻā§:
Gross DNS (Lt)
āĻ āϰā§āĻĨāĻžā§ āĻāĻŋāĻāĻŋā§āϏāĻ āĻŦāĻžāĻŽ āĻĻāĻŋāĻā§ āĻāϞā§āϞā§āĻāϝā§āĻā§āϝ Septal Deviation āĻļāύāĻžāĻā§āϤ āĻāϰā§āĻā§āύāĨ¤
Doctor-documented diagnosis/finding: Gross Left-Sided Deviated Nasal Septum.
ICD-10-CM: J34.2
āĻāώā§āϧā§āϰ āĻāĻŋāϤā§āϤāĻŋāϤ⧠Allergic Rhinitis āĻŦāĻŋāĻŦā§āĻāĻŋāϤ āĻšāϤ⧠āĻĒāĻžāϰā§, āĻāĻŋāύā§āϤ⧠āϏā§āĻāĻŋ āĻāĻŋāĻāĻŋā§āϏāĻ āϏā§āĻĒāώā§āĻāĻāĻžāĻŦā§ āϞāĻŋāĻā§āĻā§āύâāĻāĻŽāύ āĻĒā§āϰāĻŽāĻžāĻŖ āύā§āĻāĨ¤
Confidence: 0.98 for DNS; 0.65 for suspected associated allergic rhinitis.
đ§ 08. My Clinical Working Diagnosis | āĻāĻŽāĻžāϰ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻāύāĻŋāϰā§āĻŖā§
Final Working Dx: Gross Left-Sided Deviated Nasal Septum (J34.2), with Suspected Coexisting Allergic Rhinitis (J30.9 â Unconfirmed).
āĻŦāĻžāĻāϞāĻž āϰā§āĻāύāĻŋāϰā§āĻŖā§
āĻŦāĻžāĻŽ āĻĻāĻŋāĻā§ āĻāϞā§āϞā§āĻāϝā§āĻā§āϝāĻāĻžāĻŦā§ āĻŦāĻžāĻāĻāĻž āύāĻžāĻā§āϰ āĻĒāϰā§āĻĻāĻž (DNS), āϝāĻžāϰ āϏāĻā§āĻā§ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āύāĻžāĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻĨāĻžāĻāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϰā§ā§āĻā§āĨ¤
āĻāĻāĻŋ āϏāĻŦāĻā§ā§ā§ āϝā§āĻā§āϤāĻŋāϏāĻāĻāϤ working diagnosis, āϤāĻŦā§ āϰā§āĻā§āϰ āĻāĻĒāϏāϰā§āĻ āĻ āĻĒā§āϰā§āĻŖ nasal examination āĻāĻžā§āĻž associated rhinitis āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Diagnostic Confidence
| Diagnostic Component | Confidence |
|---|---|
| Documented gross left-sided DNS | 0.98 |
| DNS contributing to nasal obstruction | 0.85 |
| Associated allergic rhinitis | 0.65 |
| Chronic rhinosinusitis | 0.35 â insufficient evidence |
| Planned septoplasty | 0.75 â inferred, not documented |
đŠ 09. Definition, Etiology & Pathophysiology
A. Deviated Nasal Septum (DNS)
Definition â āϏāĻāĻā§āĻāĻž:
Deviation of the nasal septum from its normal midline position.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻŽāϧā§āϝāĻŦāϰā§āϤ⧠āĻĒāϰā§āĻĻāĻž āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻŽāĻžāĻā§āϰ āĻ āĻŦāϏā§āĻĨāĻžāύ āĻĨā§āĻā§ āĻāĻāĻĻāĻŋāĻā§ āĻŦāĻžāĻāĻāĻž āĻšā§ā§ āĻĨāĻžāĻāĻžāĨ¤
Etiology â āϰā§āĻā§āϰ āĻāĻžāϰāĻŖ
- Congenital deviation: āĻāύā§āĻŽāĻāϤāĻāĻžāĻŦā§ āύāĻžāĻā§āϰ āĻĒāϰā§āĻĻāĻž āĻŦāĻžāĻāĻāĻž āĻĨāĻžāĻāĻžāĨ¤
- Traumatic deviation: āύāĻžāĻā§ āĻāĻāĻžāϤā§āϰ āĻāĻžāϰāĻŖā§ āĻĒāϰā§āĻĻāĻž āϏāϰ⧠āϝāĻžāĻā§āĻžāĨ¤
- Developmental deviation: āĻŽā§āĻāĻŽāĻŖā§āĻĄāϞ āĻ āύāĻžāĻā§āϰ āĻŦā§āĻĻā§āϧāĻŋāϰ āϏāĻŽā§ āĻ āϏāĻŽ āĻĒāϰāĻŋāĻŦāϰā§āϤāύāĨ¤
Pathophysiology â āϰā§āĻ āϏā§āώā§āĻāĻŋāϰ āĻĒā§āϰāĻā§āϰāĻŋā§āĻž
Septal deviation â Narrowing of nasal passage â Increased airway resistance â Nasal obstruction.
āĻŦāĻžāĻāϞāĻžā§:
āύāĻžāĻā§āϰ āĻĒāϰā§āĻĻāĻž āĻŦāĻžāĻāĻāĻž â āύāĻžāĻā§āϰ āĻā§āϤāϰ⧠āĻāĻžā§āĻāĻž āĻāĻŽā§ āϝāĻžāĻā§āĻž â āĻŦāĻžāϤāĻžāϏ āĻāϞāĻžāĻāϞ⧠āĻŦāĻžāϧāĻž āĻŦā§āĻĻā§āϧāĻŋ â āύāĻžāĻ āĻŦāύā§āϧ āĻ āύā§āĻā§āϤ āĻšāĻā§āĻžāĨ¤
Confidence: 0.97
B. Allergic Rhinitis
Definition â āϏāĻāĻā§āĻāĻž:
An IgE-mediated inflammatory disease of the nasal mucosa triggered by allergens.
āĻŦāĻžāĻāϞāĻž: āϧā§āϞāĻžāĻŦāĻžāϞāĻŋ, āĻĒāϰāĻžāĻāϰā§āĻŖā§ āĻŦāĻž āĻ āύā§āϝ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻā§āύā§āϰ āϏāĻāϏā§āĻĒāϰā§āĻļā§ āύāĻžāĻā§āϰ āĻā§āϤāϰā§āϰ āĻāĻŦāϰāĻŖā§ IgE-mediated allergic inflammation āĻšāĻā§āĻžāĨ¤
Pathophysiology
Allergen exposure â IgE activation â Mast-cell activation â Histamine and leukotriene release â Nasal inflammation.
āĻŦāĻžāĻāϞāĻžā§:
āĻ ā§āϝāĻžāϞāĻžāϰā§āĻā§āύā§āϰ āϏāĻāϏā§āĻĒāϰā§āĻļ â IgE āϏāĻā§āϰāĻŋā§ āĻšāĻā§āĻž â Mast cell āĻĨā§āĻā§ histamine āĻ leukotriene āύāĻŋāĻāϏāϰāĻŖ â āύāĻžāĻā§āϰ āĻāĻŦāϰāĻŖ āĻĢā§āϞ⧠āϝāĻžāĻā§āĻž, āĻšāĻžāĻāĻāĻŋ, āĻĒāĻžāύāĻŋ āĻĒā§āĻž āĻ āύāĻžāĻ āĻŦāύā§āϧ āĻšāĻā§āĻžāĨ¤
Confidence: 0.98 for the mechanism; 0.65 for its presence in this patient.
đ§ 10. Differential Diagnosis | āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻŦāĻŋāĻāϞā§āĻĒ āϰā§āĻ
| Differential Diagnosis | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Clinical Consideration |
|---|---|---|
| Inferior turbinate hypertrophy | āύāĻžāĻā§āϰ āύāĻŋāĻā§āϰ āĻāĻžāϰāĻŦāĻŋāύā§āĻ āĻŦā§ āĻšāĻā§āĻž | āύāĻžāĻ āĻŦāύā§āϧā§āϰ āĻāĻžāϰāĻŖ āĻšāϤ⧠āĻĒāĻžāϰā§; āύāĻĨāĻŋāĻā§āĻā§āϤ āύ⧠|
| Non-allergic rhinitis | āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻāĻžā§āĻž āύāĻžāĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš | Allergic Rhinitis-āĻāϰ āĻŦāĻŋāĻāϞā§āĻĒ |
| Chronic rhinosinusitis | āĻĻā§āϰā§āĻāĻŽā§ā§āĻžāĻĻāĻŋ āύāĻžāĻ āĻ āϏāĻžāĻāύāĻžāϏā§āϰ āĻĒā§āϰāĻĻāĻžāĻš | āĻĒā§āϰā§ā§āĻāύā§ā§ symptoms āĻ objective findings āĻ āύā§āĻĒāϏā§āĻĨāĻŋāϤ |
| Nasal polyposis | āύāĻžāĻā§āϰ āĻĒāϞāĻŋāĻĒ | Endoscopy āĻāĻžā§āĻž āύāĻŋāĻļā§āĻāĻŋāϤ āύ⧠|
| Nasal valve dysfunction | āύāĻžāĻā§āϰ āĻĒā§āϰāĻŦā§āĻļāĻĒāĻĨā§āϰ āĻāĻžāϰā§āϝāĻāϤ āϏāĻŽāϏā§āϝāĻž | āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžā§ āĻŽā§āϞā§āϝāĻžā§āύāϝā§āĻā§āϝ |
Confidence: 0.95 for differential relevance; no alternative diagnosis is confirmed.
đŠ 11. Original Prescription Drug Summary | āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻāώā§āϧ
| No. | Brand | Generic | MedEx Therapeutic Class | Main Purpose |
|---|---|---|---|---|
| 1 | Biltin 20 mg | Bilastine | Anti-histamine | Allergic symptoms |
| 2 | Lumona 10 mg | Montelukast Sodium | Leukotriene receptor antagonists | Allergic airway inflammation |
| 3 | Rynex 0.05% Nasal Drop | Oxymetazoline Hydrochloride | Nasal Decongestants & Other Nasal Preparations | Temporary relief of nasal congestion |
āĻāϞā§āϞāĻŋāĻāĻŋāϤ āϤāĻŋāύāĻāĻŋ brand āĻāĻŦāĻ generic MedEx-āĻ āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤
Confidence: 0.97
đ§ 12. Complete Drug Analysis â Medicine 1
1. Biltin 20 mg Tablet
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Bilastine 20 mg â āĻŦāĻŋāϞāĻžāϏā§āĻāĻŋāύ ⧍ā§Ļ āĻŽāĻŋ.āĻā§āϰāĻž.
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Biltin â Eskayef Pharmaceuticals Ltd.
3. MedEx Alternate Brand â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Allertin 20 mg, Beltas 20 mg, Biltex 20 mg, Bilxen 20 mg.
āĻāĻāĻ generic āĻ strength-āĻāϰ āĻŦāĻŋāĻāϞā§āĻĒ; āĻāĻāϏāĻā§āĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϤāĻžāϞāĻŋāĻāĻž āύā§āĨ¤
4. MedEx Therapeutic Class â āĻĨā§āϰāĻžāĻĒāĻŋāĻāĻāĻŋāĻ āĻļā§āϰā§āĻŖāĻŋ
Anti-histamine â āĻ ā§āϝāĻžāύā§āĻāĻŋāĻšāĻŋāϏā§āĻāĻžāĻŽāĻŋāύāĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Second-generation H1-receptor antagonist â āĻĻā§āĻŦāĻŋāϤā§ā§ āĻĒā§āϰāĻāύā§āĻŽā§āϰ H1 āĻšāĻŋāϏā§āĻāĻžāĻŽāĻŋāύ āϰāĻŋāϏā§āĻĒā§āĻāϰ āĻŦā§āϞāĻāĻžāϰāĨ¤
6. Use of Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
Allergic rhinitis-āĻāϰ āĻāĻĒāϏāϰā§āĻ, āĻŦāĻŋāĻļā§āώāϤ āĻšāĻžāĻāĻāĻŋ, āύāĻžāĻ āĻā§āϞāĻāĻžāύ⧠āĻ āύāĻžāĻ āĻĻāĻŋā§ā§ āĻĒāĻžāύāĻŋ āĻĒā§āĻž āĻāĻŽāĻžāύā§āĨ¤
7. Why Prescribed in This Patient â āĻāĻ āϰā§āĻā§āϰ āĻāύā§āϝ āĻā§āύ
DNS-āĻāϰ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ allergic symptoms āϏāύā§āĻĻā§āĻš āĻāϰ⧠āĻāĻŋāĻāĻŋā§āϏāĻ āĻāώā§āϧāĻāĻŋ āĻĻāĻŋāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
Patient-specific confidence: 0.70.
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Headache, dizziness, somnolence, fatigue.
āĻŦāĻžāĻāϞāĻž: āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž, āĻŽāĻžāĻĨāĻž āĻā§āϰāĻž, āĻā§āĻŽāĻā§āĻŽ āĻāĻžāĻŦ āĻ āĻā§āϞāĻžāύā§āϤāĻŋāĨ¤
9. Direct MedEx Link â āϏāϰāĻžāϏāϰāĻŋ āĻŽā§āĻĄā§āĻā§āϏ āϞāĻŋāĻāĻ
10. Unit Price, Strip Price & Other Strengths â āĻŽā§āϞā§āϝ āĻ āĻ āύā§āϝāĻžāύā§āϝ āĻŽāĻžāϤā§āϰāĻž
Unit price: ā§ŗ15.00
Strip price: ā§ŗ150.00 (10 tablets)
Other available formulations:
- Biltin 10 mg dispersible tablet
- Biltin 12.5 mg/5 ml oral solution
11. Mechanism of Action â āĻāĻžāϰā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ
Selective H1-receptor blockade â Histamine effects reduced â Allergic symptoms decrease.
āĻŦāĻžāĻāϞāĻž: Histamine-āĻāϰ āĻāĻžāĻ āĻŦāĻžāϧāĻžāĻā§āϰāϏā§āϤ āĻāϰ⧠āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻĒāϏāϰā§āĻ āĻāĻŽāĻžā§āĨ¤
12. Drug Indications â āύāĻŋāϰā§āĻĻā§āĻļāĻŋāϤ āϰā§āĻ
Allergic rhinoconjunctivitis and urticaria.
āĻŦāĻžāĻāϞāĻž: āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āύāĻžāĻ āĻ āĻā§āĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻāĻŦāĻ āĻāĻžāĻāĻž āĻāĻžāĻāĻž āĻā§āϞāĻāĻžāύāĻŋāϝā§āĻā§āϤ āĻĢā§āϏāĻā§ā§āĻŋāĨ¤
13. Drug Interactions & Contraindications â āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āĻĒā§āϰāϤāĻŋāύāĻŋāϰā§āĻĻā§āĻļāύāĻž
Ketoconazole, erythromycin, cyclosporine āĻ diltiazem bilastine exposure āĻŦāĻžā§āĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤
Bilastine hypersensitivity āĻĨāĻžāĻāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻŋāώāĻŋāĻĻā§āϧāĨ¤
14. Precautions & Warnings â āϏāϤāϰā§āĻāϤāĻž
āĻā§āĻŽāĻā§āĻŽ āĻāĻžāĻŦ āĻŦāĻž āĻŽāĻžāĻĨāĻž āĻā§āϰāĻž āĻšāϞ⧠āĻāĻžā§āĻŋ āĻāĻžāϞāĻžāύā§āϤ⧠āϏāϤāϰā§āĻāϤāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤ Severe renal impairment-āĻāϰ āϰā§āĻā§āϰ concomitant interacting drugs āĻŦāĻŋāĻļā§āώāĻāĻžāĻŦā§ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
15. Dosage & Administration â āĻŽāĻžāϤā§āϰāĻž āĻ āϏā§āĻŦāύāĻŦāĻŋāϧāĻŋ
Standard adult dose: 20 mg once daily.
āĻāĻžāϞāĻŋ āĻĒā§āĻā§, āĻāĻžāĻŦāĻžāϰā§āϰ āĻ āύā§āϤāϤ āĻāĻ āĻāĻŖā§āĻāĻž āĻāĻā§ āĻ āĻĨāĻŦāĻž āĻĻā§āĻ āĻāĻŖā§āĻāĻž āĻĒāϰ⧠āĻā§āϰāĻšāĻŖ āĻāϰāĻž āĻšā§āĨ¤
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠⧧ā§ĢāĻāĻŋ āĻā§āϝāĻžāĻŦāϞā§āĻ āϞā§āĻāĻž āĻāĻā§ āĻŦāϞ⧠āĻŽāύ⧠āĻšāĻā§āĻā§ āĻāĻŦāĻ āĻĻāĻŋāύ⧠āĻāĻāĻŦāĻžāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āύāĻŋāϰā§āĻĻā§āĻļ āϰā§ā§āĻā§āĨ¤
16. Pregnancy & Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
Limited human pregnancy data; avoid unless clinically justified.
āĻŦāĻžāĻāϞāĻž: āĻĒāϰā§āϝāĻžāĻĒā§āϤ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āϤāĻĨā§āϝ āύāĻž āĻĨāĻžāĻāĻžā§ āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻžā§ āĻĒā§āϰā§ā§āĻāύ āĻāĻžā§āĻž āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻā§āĻžāύ⧠āĻāĻāĻŋāϤāĨ¤ āϏā§āϤāύā§āϝāĻĻāĻžāύāĻāĻžāϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻŽā§āϞā§āϝāĻžā§āύ āĻĒā§āϰā§ā§āĻāύāĨ¤
17. Other Combinations in MedEx â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŽā§āĻŦāĻŋāύā§āĻļāύ
āϝāĻžāĻāĻžāĻāĻā§āϤ MedEx Bilastine āϤāĻžāϞāĻŋāĻāĻžā§ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻā§āύ⧠fixed-dose combination āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§āύāĻŋāĨ¤ āĻŦāĻŋāĻāĻŋāύā§āύ strength āĻ formulation āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤
Medicine data confidence: 0.97 | Why prescribed in this patient: 0.70.
đ§ 13. Complete Drug Analysis â Medicine 2
2. Lumona 10 mg Tablet
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Montelukast Sodium 10 mg â āĻŽāύā§āĻāĻŋāϞā§āĻāĻžāϏā§āĻ āϏā§āĻĄāĻŋā§āĻžāĻŽāĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Lumona â Eskayef Pharmaceuticals Ltd.
3. MedEx Alternate Brand â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Montair 10 mg, Montene 10 mg, Montex 10 mg.
4. MedEx Therapeutic Class â āĻĨā§āϰāĻžāĻĒāĻŋāĻāĻāĻŋāĻ āĻļā§āϰā§āĻŖāĻŋ
Leukotriene receptor antagonists â āϞāĻŋāĻāĻā§āĻā§āϰāĻŋā§ā§āύ āϰāĻŋāϏā§āĻĒā§āĻāϰ āĻĒā§āϰāϤāĻŋāϰā§āϧāĻāĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Cysteinyl leukotriene receptor-1 antagonist (CysLT1 antagonist).
āĻŦāĻžāĻāϞāĻž: CysLT1 āϰāĻŋāϏā§āĻĒā§āĻāϰā§āϰ āĻāĻžāϰā§āϝāĻā§āϰāĻŽ āĻŦāĻžāϧāĻžāĻā§āϰāϏā§āϤāĻāĻžāϰ⧠āĻāώā§āϧāĨ¤
6. Use of Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
Asthma control āĻ āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ āϰā§āĻā§āϰ Allergic Rhinitis symptoms āύāĻŋā§āύā§āϤā§āϰāĻŖāĨ¤
7. Why Prescribed in This Patient â āĻāĻ āϰā§āĻā§āϰ āĻāύā§āϝ āĻā§āύ
āϏāĻŽā§āĻāĻžāĻŦā§āϝ allergic nasal inflammation āύāĻŋā§āύā§āϤā§āϰāĻŖā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠āĻĻā§āĻā§āĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
DNS-āĻāϰ āĻŦāĻžāĻāĻāĻž āĻĒāϰā§āĻĻāĻž āĻāĻāĻŋ āϏā§āĻāĻž āĻāϰāϤ⧠āĻĒāĻžāϰ⧠āύāĻžāĨ¤
Patient-specific confidence: 0.70.
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Headache, abdominal pain, gastrointestinal discomfort, nausea.
āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻŦāĻŋāϰāϞ āĻŦāĻž āĻā§āϰā§āϤāϰ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž: Sleep disturbance, nightmares, mood changes, depression, suicidal thoughts/actions.
āĻŦāĻžāĻāϞāĻž: āĻā§āĻŽā§āϰ āϏāĻŽāϏā§āϝāĻž, āĻĻā§āĻāϏā§āĻŦāĻĒā§āύ, āĻāĻāϰāĻŖ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ, āĻŦāĻŋāώāĻŖā§āĻŖāϤāĻž āĻāĻŦāĻ āĻāϤā§āĻŽāĻšāϤā§āϝāĻžāϰ āĻāĻŋāύā§āϤāĻž āĻŦāĻž āĻāĻāϰāĻŖā§āϰ āĻā§āĻāĻāĻŋāĨ¤
9. Direct MedEx Link â āϏāϰāĻžāϏāϰāĻŋ āĻŽā§āĻĄā§āĻā§āϏ āϞāĻŋāĻāĻ
10. Unit Price, Strip Price & Other Strengths â āĻŽā§āϞā§āϝ āĻ āĻ āύā§āϝāĻžāύā§āϝ āĻŽāĻžāϤā§āϰāĻž
Unit price: ā§ŗ12.00
Strip price: ā§ŗ168.00 (14 tablets)
Other forms:
- 4 mg flash tablet
- 5 mg flash tablet
- 4 mg/3.5 gm oral granules
11. Mechanism of Action â āĻāĻžāϰā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ
Blocks CysLT1 receptors â Reduces leukotriene-mediated inflammatory effects.
āĻŦāĻžāĻāϞāĻž: Leukotriene-āĻāϰ āĻāĻžāϰā§āϝāĻā§āϰāĻŽ āĻŦāĻžāϧāĻž āĻĻāĻŋā§ā§ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšā§āϰ āĻāĻŋāĻā§ āĻĒā§āϰāĻāĻžāĻŦ āĻāĻŽāĻžā§āĨ¤
12. Drug Indications â āύāĻŋāϰā§āĻĻā§āĻļāĻŋāϤ āϰā§āĻ
Asthma maintenance, exercise-induced bronchoconstriction prevention and selected allergic rhinitis.
āĻŦāĻžāĻāϞāĻž: āĻšāĻžāĻāĻĒāĻžāύāĻŋāϰ āĻĻā§āϰā§āĻāĻŽā§ā§āĻžāĻĻāĻŋ āύāĻŋā§āύā§āϤā§āϰāĻŖ, āĻŦā§āϝāĻžā§āĻžāĻŽāĻāύāĻŋāϤ āĻļā§āĻŦāĻžāϏāύāĻžāϞāĻŋāϰ āϏāĻāĻā§āĻāύ āĻĒā§āϰāϤāĻŋāϰā§āϧ āĻāĻŦāĻ āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻ āϰāĻžāĻāύāĻžāĻāĻāĻŋāϏāĨ¤
13. Drug Interactions & Contraindications â āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āĻĒā§āϰāϤāĻŋāύāĻŋāϰā§āĻĻā§āĻļāύāĻž
Phenobarbital āĻ rifampicin-āĻāϰ āĻŽāϤ⧠enzyme inducer montelukast exposure āĻāĻŽāĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤
Hypersensitivity āĻĨāĻžāĻāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻŋāώāĻŋāĻĻā§āϧāĨ¤
14. Precautions & Warnings â āϏāϤāϰā§āĻāϤāĻž
FDA Boxed Warning: Allergic Rhinitis-āĻāϰ āĻā§āώā§āϤā§āϰ⧠āĻ āύā§āϝ āĻāĻĒāϝā§āĻā§āϤ allergy medicine āĻāĻžāϰā§āϝāĻāϰ āύāĻž āĻšāϞ⧠āĻŦāĻž āϏāĻšā§āϝ āύāĻž āĻšāϞ⧠Montelukast āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
āĻāĻāĻŋ āϏāĻžāϧāĻžāϰāĻŖ mild allergic rhinitis-āĻāϰ first-choice medicine āύā§āĨ¤
FDA āĻā§āϰā§āϤāϰ neuropsychiatric adverse effects āϏāĻŽā§āĻĒāϰā§āĻā§ āϏāϤāϰā§āĻ āĻāϰā§āĻā§āĨ¤ āύāϤā§āύ mood āĻŦāĻž behavioural symptoms āĻĻā§āĻāĻž āĻĻāĻŋāϞ⧠āĻāώā§āϧ āĻŦāύā§āϧ āĻāϰ⧠āĻĻā§āϰā§āϤ prescriber-āĻāϰ āϏāĻā§āĻā§ āϝā§āĻāĻžāϝā§āĻ āĻĒā§āϰā§ā§āĻāύāĨ¤
15. Dosage & Administration â āĻŽāĻžāϤā§āϰāĻž āĻ āϏā§āĻŦāύāĻŦāĻŋāϧāĻŋ
Adult standard dose: 10 mg once daily.
āĻāĻžāĻŦāĻžāϰā§āϰ āϏāĻā§āĻā§ āĻŦāĻž āĻāĻžā§āĻž āύā§āĻā§āĻž āϝāĻžā§āĨ¤
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠ā§Ŧā§ĻāĻāĻŋ āĻā§āϝāĻžāĻŦāϞā§āĻ āĻāĻŦāĻ āĻĻāĻŋāύ⧠āĻāĻāĻŦāĻžāϰā§āϰ āύāĻŋāϰā§āĻĻā§āĻļ āĻĒā§āĻž āϝāĻžāĻā§āĻā§āĨ¤ āϤāĻŦā§ allergic rhinitis-āĻāϰ āĻāύā§āϝ ā§Ŧā§Ļ āĻĻāĻŋāύā§āϰ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āĻāϞāĻžāĻĻāĻžāĻāĻžāĻŦā§ āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
16. Pregnancy & Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
Benefit-risk assessment āĻĒā§āϰā§ā§āĻāύāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύāĻāĻžāϞ⧠āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āĻāĻŦāĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻā§āĻāĻāĻŋ āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰ⧠āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āύāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
17. Other Combinations in MedEx â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŽā§āĻŦāĻŋāύā§āĻļāύ
āϝāĻžāĻāĻžāĻāĻā§āϤ Lumona product page-āĻ fixed-dose combination āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤ āύā§āĻāĨ¤ āϤāĻžāĻ āĻā§āύ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ combined brand āϝāĻžāĻāĻžāĻ āĻāĻžā§āĻž āĻāϞā§āϞā§āĻ āĻāϰāĻž āĻšāĻā§āĻā§ āύāĻžāĨ¤
Medicine data confidence: 0.97 | Patient-specific indication: 0.70.
đ§ 14. Complete Drug Analysis â Medicine 3
3. Rynex 0.05% Nasal Drop
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Oxymetazoline Hydrochloride 0.05% â āĻ āĻā§āϏāĻŋāĻŽā§āĻāĻžāĻā§āϞāĻŋāύ āĻšāĻžāĻāĻĄā§āϰā§āĻā§āϞā§āϰāĻžāĻāĻĄāĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Rynex â Incepta Pharmaceuticals Ltd.
3. MedEx Alternate Brand â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Afrin, Oxynex, Oxymist, Oxyzolin â āĻāĻāĻ generic-āĻāϰ āĻāĻĒāϝā§āĻā§āϤ nasal formulationsāĨ¤
4. MedEx Therapeutic Class â āĻĨā§āϰāĻžāĻĒāĻŋāĻāĻāĻŋāĻ āĻļā§āϰā§āĻŖāĻŋ
Nasal Anti-histamine Preparations, Nasal Decongestants & Other Nasal Preparations.
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Topical alpha-adrenergic agonist / sympathomimetic nasal decongestant.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āϰāĻā§āϤāύāĻžāϞāĻŋ āϏāĻāĻā§āĻāĻŋāϤāĻāĻžāϰ⧠āϏā§āĻĨāĻžāύā§ā§ āĻāώā§āϧāĨ¤
6. Use of Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
Temporary relief of nasal congestion.
āĻŦāĻžāĻāϞāĻž: āϏāĻžāĻŽā§āĻŋāĻāĻāĻžāĻŦā§ āύāĻžāĻ āĻŦāύā§āϧ āĻāĻŽāĻžāύā§āĨ¤
7. Why Prescribed in This Patient â āĻāĻ āϰā§āĻā§āϰ āĻāύā§āϝ āĻā§āύ
DNS-āĻāϰ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ nasal mucosal swelling āĻĨāĻžāĻāϞ⧠āϏāĻžāĻŽā§āĻŋāĻāĻāĻžāĻŦā§ airflow āĻāύā§āύāϤ āĻāϰāĻžāϰ āĻāύā§āϝ āĻĻā§āĻā§āĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Patient-specific confidence: 0.85.
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Local irritation, burning sensation, dryness and sneezing.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§ āĻā§āĻŦāĻžāϞāĻžāĻĒā§ā§āĻž, āĻļā§āώā§āĻāϤāĻž āĻ āĻšāĻžāĻāĻāĻŋāĨ¤
Important: Prolonged use can cause rebound congestion or rhinitis medicamentosa.
āĻŦāĻžāĻāϞāĻž: āĻĻā§āϰā§āĻāĻĻāĻŋāύ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧠āĻāώā§āϧā§āϰ āĻāĻžāϰāĻŖā§āĻ āύāĻžāĻ āĻāϰāĻ āĻŦā§āĻļāĻŋ āĻŦāύā§āϧ āĻšā§ā§ āϝāĻžāĻā§āĻžāϰ āϏāĻŽāϏā§āϝāĻž āϤā§āϰāĻŋ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
9. Direct MedEx Link â āϏāϰāĻžāϏāϰāĻŋ āĻŽā§āĻĄā§āĻā§āϏ āϞāĻŋāĻāĻ
Rynex 0.05% Nasal Drop â MedEx
10. Unit Price, Strip Price & Other Strengths â āĻŽā§āϞā§āϝ āĻ āĻ āύā§āϝāĻžāύā§āϝ āĻŽāĻžāϤā§āϰāĻž
10 ml bottle: ā§ŗ45.00
Strip price āĻĒā§āϰāϝā§āĻā§āϝ āύā§āĨ¤
Other formulations:
- 0.025% nasal drop
- 0.05% nasal spray
11. Mechanism of Action â āĻāĻžāϰā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ
Alpha-adrenergic receptor activation â Nasal mucosal vasoconstriction â Reduced mucosal swelling.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āϰāĻā§āϤāύāĻžāϞāĻŋ āϏāĻāĻā§āĻāĻŋāϤ āĻāϰ⧠āĻĢā§āϞāĻž āĻāĻŽāĻžā§ āĻāĻŦāĻ āϏāĻžāĻŽā§āĻŋāĻāĻāĻžāĻŦā§ āĻļā§āĻŦāĻžāϏ āĻāϞāĻžāĻāϞā§āϰ āĻĒāĻĨ āĻĒā§āϰāĻļāϏā§āϤ āĻāϰā§āĨ¤
12. Drug Indications â āύāĻŋāϰā§āĻĻā§āĻļāĻŋāϤ āϰā§āĻ
Nasal congestion associated with rhinitis, upper respiratory allergy, common cold and selected sinonasal conditions.
13. Drug Interactions & Contraindications â āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āĻĒā§āϰāϤāĻŋāύāĻŋāϰā§āĻĻā§āĻļāύāĻž
MAO inhibitors-āĻāϰ āϏāĻā§āĻā§ āĻŦāĻž āϏā§āĻā§āϞ⧠āĻŦāύā§āϧ āĻāϰāĻžāϰ ā§§ā§Ē āĻĻāĻŋāύā§āϰ āĻŽāϧā§āϝ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻā§āĻžāϤ⧠āĻšāĻŦā§āĨ¤
Cardiovascular disease, hyperthyroidism, angle-closure glaucoma āĻ āĻ āύā§āϝāĻžāύā§āϝ āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤ contraindications āĻŽā§āϞā§āϝāĻžā§āύ āĻĒā§āϰā§ā§āĻāύāĨ¤
14. Precautions & Warnings â āϏāϤāϰā§āĻāϤāĻž
ARIA 2024â2025 guidance recommends against long-term intranasal decongestant use beyond five days.
āĻ āϰā§āĻĨāĻžā§ Oxymetazoline āύāĻŋā§āĻŽāĻŋāϤ āĻĻā§āϰā§āĻāĻĻāĻŋāύ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻāĻāĻŋāϤ āύā§āĨ¤
āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āύāĻŋāĻā§āϰ āύāĻŋāϰā§āĻĻā§āĻļāĻāĻŋ āϏāĻŽā§āĻāĻŦāϤ āϞā§āĻāĻž āϰā§ā§āĻā§:
ā§Š āĻĢā§āĻāĻāĻž Ã ā§Š āĻŦāĻžāϰ, āύāĻžāĻā§āĨ¤
āĻāĻŋāύā§āϤ⧠āĻšāĻžāϤā§āϰ āϞā§āĻāĻžāϰ āĻāĻžāϰāĻŖā§ duration āϏāĻŽā§āĻĒā§āϰā§āĻŖ āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤
āĻāĻĻāĻŋāĻā§ MedEx-āĻ 0.05% nasal drops-āĻāϰ standard adult instructions āĻšāϞ⧠āĻĒā§āϰāϤāĻŋ āύāĻžāϏāĻžāϰāύā§āϧā§āϰ⧠⧍âā§Š āĻĢā§āĻāĻāĻž āĻĻāĻŋāύ⧠āĻĻā§āĻāĻŦāĻžāϰāĨ¤
āϏā§āϤāϰāĻžāĻ āĻĻāĻŋāύ⧠āϤāĻŋāύāĻŦāĻžāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻŦāĻž āĻĻā§āϰā§āĻāĻŽā§ā§āĻžāĻĻāĻŋ duration āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϏāĻā§āĻā§ āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
15. Dosage & Administration â āĻŽāĻžāϤā§āϰāĻž āĻ āϏā§āĻŦāύāĻŦāĻŋāϧāĻŋ
MedEx adult dose: 2â3 drops in each nostril twice daily.
āϏā§āĻŦāϞā§āĻĒāĻŽā§ā§āĻžāĻĻāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ; āϏāĻžāϧāĻžāϰāĻŖāϤ ā§Šâā§Ģ āĻĻāĻŋāύā§āϰ āĻŽāϧā§āϝ⧠āϏā§āĻŽāĻžāĻŦāĻĻā§āϧ āϰāĻžāĻāĻž āϝā§āĻā§āϤāĻŋāϏāĻāĻāϤ, āϝāĻĻāĻŋ treating clinician āĻ āύā§āϝāĻāĻžāĻŦā§ āĻŽā§āϞā§āϝāĻžā§āύ āύāĻž āĻāϰā§āύāĨ¤
16. Pregnancy & Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
Safety data limited; use requires medical assessment.
āĻŦāĻžāĻāϞāĻž: āĻĒāϰā§āϝāĻžāĻĒā§āϤ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āϤāĻĨā§āϝ āύā§āĻ; āĻĒā§āϰā§ā§āĻāύ āĻāĻžā§āĻž āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻā§āĻžāύ⧠āĻāĻāĻŋāϤāĨ¤
17. Other Combinations in MedEx â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŽā§āĻŦāĻŋāύā§āĻļāύ
MedEx-āĻ Oxymetazoline-āĻāϰ cream āĻ ophthalmic formulations-āĻ āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤ āϰā§ā§āĻā§āĨ¤ āĻāĻā§āϞ⧠āĻ āύā§āϝ formulation, nasal drop-āĻāϰ fixed-dose combination āύā§āĨ¤
Medicine data confidence: 0.98 | Prescription dosing interpretation: 0.65.
đŠ 15. MedEx-Based Alternative Drug Options | āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§ āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤ āĻŦāĻŋāĻāϞā§āĻĒ āĻāώā§āϧ
Important: āύāĻŋāĻā§āϰ āϤāĻžāϞāĻŋāĻāĻžāĻāĻŋ āĻāĻ āϰā§āĻā§āϰ āĻāύā§āϝ āύāϤā§āύ prescription āύā§āĨ¤ Allergic Rhinitis āĻ nasal congestion-āĻāϰ āĻā§āώā§āϤā§āϰ⧠āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§ MedEx-āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤ āϏāĻŽā§āĻāĻžāĻŦā§āϝ therapeutic options āĻĻā§āĻāĻžāύ⧠āĻšā§ā§āĻā§āĨ¤
| No. | MedEx Brand | Generic | Therapeutic Class | Specific Clinical Purpose |
|---|---|---|---|---|
| 1 | Nasonex Nasal Spray | Mometasone Furoate | Nasal Steroid Preparations | Allergic inflammation āĻ congestion āĻāĻŽāĻžāύ⧠|
| 2 | Fexofast 120 mg | Fexofenadine | Anti-histamine | āĻšāĻžāĻāĻāĻŋ, āύāĻžāĻ āĻā§āϞāĻāĻžāύā§, āĻĒāĻžāύāĻŋ āĻĒā§āĻž āĻāĻŽāĻžāύ⧠|
| 3 | Montair 10 mg | Montelukast | Leukotriene receptor antagonists | āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ allergic rhinitis/asthma āϰā§āĻā§ |
| 4 | NaSal 0.9% / Sodium Chloride brands | Sodium Chloride | Saline Nasal Preparation | Nasal moisturisation āĻ mucus clearance |
| 5 | Oxymetazoline Alternative Brands | Oxymetazoline | Nasal Decongestants | āϏā§āĻŦāϞā§āĻĒāĻŽā§ā§āĻžāĻĻāĻŋ nasal congestion relief |
Clinical interpretation:
āĻŦāϰā§āϤāĻŽāĻžāύ ARIA guidance āĻ āύā§āϝāĻžā§ā§ persistent āĻŦāĻž bothersome allergic rhinitis-āĻāϰ āĻā§āώā§āϤā§āϰ⧠intranasal corticosteroid āĻāĻāĻāĻŋ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ evidence-based treatment optionāĨ¤
āϤāĻŦā§ āĻāĻāĻŋ āύāĻžāĻā§āϰ āĻŦāĻžāĻāĻāĻž āĻĒāϰā§āĻĻāĻž āϏā§āĻāĻž āĻāϰ⧠āύāĻžāĨ¤ Structural obstruction āĻāĻŦāĻ mucosal inflammationâāĻĻā§āĻāĻŋ āĻĒā§āĻĨāĻ therapeutic targetāĨ¤
Confidence: 0.96
đ§ 16. Treatment Plan, Doctor’s Diagnosis Comparison & Prescription Demo
A. Doctor’s Dx vs My Working Dx
đĸ Similarities â āĻŽāĻŋāϞ
- Doctor: Gross DNS (Lt).
- My assessment: Gross Left-Sided Deviated Nasal Septum.
- āĻĻā§āĻā§āϤā§āĻ āύāĻžāĻā§āϰ āĻĒāϰā§āĻĻāĻž āĻŦāĻžāĻŽ āĻĻāĻŋāĻā§ āĻāϞā§āϞā§āĻāϝā§āĻā§āϝāĻāĻžāĻŦā§ āĻŦāĻžāĻāĻāĻž āĻĨāĻžāĻāĻžāϰ finding āĻāĻāĻāĨ¤
- Medications suggest that the physician may also be treating nasal allergic or inflammatory symptoms.
đ Differences â āĻ āĻŽāĻŋāϞ
- āĻāĻŋāĻāĻŋā§āϏāĻ Allergic Rhinitis āϏā§āĻĒāώā§āĻāĻāĻžāĻŦā§ āϞā§āĻā§āύāύāĻŋ; āĻāĻŽāĻžāϰ assessment-āĻ āĻāĻāĻŋ suspected associated conditionāĨ¤
- Nasal obstruction āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ C/C-āϤ⧠āϞā§āĻāĻž āύā§āĻ; āĻāĻāĻŋ āĻāĻāĻāĻŋ clinical inferenceāĨ¤
- Septoplasty āĻĒāϰāĻŋāĻāϞā§āĻĒāύāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻāĻā§, āĻāĻŋāύā§āϤ⧠definitive surgical plan āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϞā§āĻāĻž āύā§āĻāĨ¤
Comparison Conclusion
The documented DNS finding and my primary working diagnosis are consistent.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āύāĻĨāĻŋāĻā§āĻā§āϤ āĻŽā§āϞ finding āĻāĻŦāĻ āĻāĻŽāĻžāϰ āĻĒā§āϰāϧāĻžāύ working diagnosis āĻāĻāĻāĨ¤ āĻĒāĻžāϰā§āĻĨāĻā§āϝ āĻšāϞā§, āĻāĻŽāĻŋ āϏāĻŽā§āĻāĻžāĻŦā§āϝ associated allergic rhinitis āϝā§āĻā§āϤ āĻāϰā§āĻāĻŋâāϝā§āĻāĻŋ āĻāĻāύ⧠āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤
Comparison confidence: 0.96 for DNS agreement; 0.65 for suspected rhinitis.
B. Guideline-Based Management Plan | āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒāϰāĻŋāĻāϞā§āĻĒāύāĻž
Step 1 â Confirm symptom pattern: āύāĻžāĻ āĻŦāύā§āϧā§āϰ āϏāĻŽā§āĻāĻžāϞ, āĻĒāĻžāĻļ, āϤā§āĻŦā§āϰāϤāĻž, āĻā§āĻŽā§āϰ āϏāĻŽāϏā§āϝāĻž āĻ allergy symptoms āύāĻĨāĻŋāĻā§āĻā§āϤ āĻāϰāĻžāĨ¤
Step 2 â Complete nasal examination: Anterior rhinoscopy āĻ āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ nasal endoscopy āĻāϰ⧠septal deviation, turbinate hypertrophy, nasal polyps āĻ āĻ āύā§āϝ obstruction āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāĻžāĨ¤
Step 3 â Treat associated inflammation: Allergic Rhinitis āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāϞ⧠guideline-based intranasal treatment āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻžāĨ¤ Montelukast-āĻāϰ āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āĻ safety āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāĻžāĨ¤
Step 4 â Review investigations: āĻāĻā§ āĻĻā§āĻā§āĻž āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ, clinical indication āĻ operative risk āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻāϰāĻžāĨ¤
Step 5 â Assess need for surgery: Persistent troublesome nasal obstruction āĻĨāĻžāĻāϞ⧠ENT specialist-āĻāϰ āĻŽāĻžāϧā§āϝāĻŽā§ Septoplasty assessment āĻāϰāĻžāĨ¤
⧍ā§Ļā§¨ā§Š āϏāĻžāϞā§āϰ BMJ randomised trial-āĻ āĻāĻĒāϝā§āĻā§āϤ symptomatic septal deviation āϰā§āĻā§āĻĻā§āϰ āĻā§āώā§āϤā§āϰ⧠septoplasty medical management-āĻāϰ āϤā§āϞāύāĻžā§ āĻāĻžāϞ⧠symptom improvement āĻĻā§āĻāĻŋā§ā§āĻā§āĨ¤ āϤāĻŦā§ āĻāĻ āϰā§āĻā§āϰ surgical eligibility āĻāĻāύ⧠āĻĒā§āϰāϤāĻŋāώā§āĻ āĻŋāϤ āύā§āĨ¤
Management confidence: 0.96
C. Clinical Prescription Demo | āĻļāĻŋāĻā§āώāĻžāĻŽā§āϞāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āύāĻŽā§āύāĻž
This is an illustrative clinical record, not a replacement for an examination-based prescription.
ENT â Clinical Working Assessment
Patient: Adult male, 32 years
Source date: 09 October 2026
C/C: Not documented. Suspected nasal obstruction; requires history confirmation.
History: Not available.
O/E: Physician-documented gross DNS (Lt). Additional nasal findings not available.
Provisional Dx:
1. Gross Left-Sided Deviated Nasal Septum â J34.2
2. Suspected Coexisting Allergic Rhinitis â J30.9 (Unconfirmed)
Investigations ordered in source prescription: CBC, BT, CT, Blood Urea, RBS, ECG, Chest X-ray PA, PNS X-ray OM View, Blood Group, HBsAg.
Management: Review symptom severity, nasal examination, previously ordered investigations, treatment response and indications for septoplasty.
Medication reconciliation: Verify original Biltin, Lumona and Rynex directions. Review the indication and neuropsychiatric safety of montelukast; clarify oxymetazoline frequency and duration before continued use.
Follow-up: ENT review after examination and available results.
Final diagnosis status: Working assessment; not independently confirmed.
đŠ 17. Final Clinical Assessment, Referral & References
Final Diagnosis for Website | āĻā§ā§āĻŦāϏāĻžāĻāĻā§āϰ āĻāύā§āϝ āϰā§āĻāύāĻŋāϰā§āĻŖā§
Gross Left-Sided Deviated Nasal Septum with Suspected Coexisting Allergic Rhinitis
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻĒāϰā§āĻĻāĻž āĻāϞā§āϞā§āĻāϝā§āĻā§āϝāĻāĻžāĻŦā§ āĻŦāĻžāĻŽ āĻĻāĻŋāĻā§ āĻŦāĻžāĻāĻāĻž, āϝāĻžāϰ āϏāĻā§āĻā§ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āύāĻžāĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻĨāĻžāĻāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϰā§ā§āĻā§āĨ¤
Recommended Department | āĻā§āύ āĻŦāĻŋāĻāĻžāĻā§ āϰā§āĻĢāĻžāϰ āĻāϰāĻŦā§āύ?
Primary referral: ENT / Otolaryngology â āύāĻžāĻ, āĻāĻžāύ āĻ āĻāϞāĻž āĻŦāĻŋāĻļā§āώāĻā§āĻāĨ¤
āĻŦāĻŋāĻļā§āώāϤ āϝāĻŋāύāĻŋ nasal obstruction, septal deviation āĻ septoplasty āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰā§āύāĨ¤
Allergic Rhinitis āĻāĻāĻŋāϞ āĻŦāĻž āĻāĻŋāĻāĻŋā§āϏāĻžā§ āύāĻŋā§āύā§āϤā§āϰāĻŖāĻšā§āύ āĻšāϞ⧠Allergy/Clinical Immunology specialist-āĻāϰ āĻŽāϤāĻžāĻŽāϤāĻ āĻŦāĻŋāĻŦā§āĻāύāĻžāϝā§āĻā§āϝāĨ¤
Referral confidence: 0.98
Overview / Summary | āϏāĻžāϰāϏāĻāĻā§āώā§āĻĒ
āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϏāĻŦāĻā§ā§ā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻŦāĻŋāώ⧠āĻšāϞ⧠Gross DNS (Lt)âāĻ āϰā§āĻĨāĻžā§ āύāĻžāĻā§āϰ āĻĒāϰā§āĻĻāĻž āĻāϞā§āϞā§āĻāϝā§āĻā§āϝāĻāĻžāĻŦā§ āĻŦāĻžāĻŽ āĻĻāĻŋāĻā§ āĻŦāĻžāĻāĻāĻž āĻĨāĻžāĻāĻžāϰ āĻāĻŋāĻāĻŋā§āϏāĻ-āύāĻĨāĻŋāĻā§āĻā§āϤ findingāĨ¤
Biltin, Lumona āĻ Rynex-āĻāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻĨā§āĻā§ associated allergic or inflammatory nasal symptoms āύāĻŋā§āύā§āϤā§āϰāĻŖā§āϰ āĻā§āώā§āĻāĻž āĻ āύā§āĻŽāĻžāύ āĻāϰāĻž āϝāĻžā§āĨ¤ āĻāĻŋāύā§āϤ⧠āĻā§āĻŦāϞ āĻāĻ āĻāώā§āϧ āĻĻā§āĻā§ Allergic Rhinitis āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤
āĻĒāϰā§āĻā§āώāĻžāϰ āϤāĻžāϞāĻŋāĻāĻž preoperative preparation-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϤā§āϰāĻŋ āĻāϰā§; āϤāĻŦā§ āĻ āϏā§āϤā§āϰā§āĻĒāĻāĻžāϰ āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āĻšā§ā§āĻā§âāĻāĻŽāύ āĻĻāĻžāĻŦāĻŋ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Overall confidence: 0.86 for the combined clinical interpretation.
Actionable Steps | āĻĒāϰāĻŦāϰā§āϤ⧠āĻāϰāĻŖā§ā§
āĻĒā§āϰāĻĨāĻŽā§ āĻĒā§āϰā§āĻŖ nasal history, anterior rhinoscopy āĻāĻŦāĻ āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ endoscopy āϏāĻŽā§āĻĒāύā§āύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤ āϤāĻžāϰāĻĒāϰ investigation results āĻ symptom severity āĻ āύā§āϝāĻžā§ā§ medical management āĻŦāύāĻžāĻŽ septoplasty āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤ āĻŦāĻŋāĻļā§āώāĻāĻžāĻŦā§ Montelukast-āĻāϰ indication āĻāĻŦāĻ Rynex-āĻāϰ dosing duration āϝāĻžāĻāĻžāĻ āĻĒā§āϰā§ā§āĻāύāĨ¤
Confidence: 0.97
Reference List | āĻĒā§āϰāĻŽāĻžāĻŖāĻāĻŋāϤā§āϤāĻŋāĻ āϤāĻĨā§āϝāϏā§āϤā§āϰ
Authoritative Textbooks
- Dhingra PL, Dhingra S. Diseases of Ear, Nose and Throat & Head and Neck Surgery. Nasal septum, nasal obstruction and rhinitis-related chapters. āϏāĻāϏā§āĻāϰāĻŖāĻā§āĻĻā§ chapter āĻ page āĻĒāϰāĻŋāĻŦāϰā§āϤāĻŋāϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Flint PW, et al. Cummings Otolaryngology: Head and Neck Surgery. 7th edition. Elsevier; 2021. Nasal obstruction and septal surgery-related chapters.
- Harrison’s Principles of Internal Medicine. 22nd edition. McGraw Hill; 2025. Allergy and clinical immunology-related sections.
International Guidelines
- ARIAâEAACI Guidelines, 2024â2025 Revision. Intranasal treatment recommendations for allergic rhinitis.
- American Academy of OtolaryngologyâHead and Neck Surgery. Clinical Indicators: Septoplasty; 2014.
- NICE NG45. Routine Preoperative Tests for Elective Surgery; 2016.
- US FDA. Boxed Warning on Montelukast: Serious Mental Health Side Effects; 2020.
Peer-Reviewed Research with Verified DOI
- Bousquet J, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA)âEAACI Guidelinesâ2024â2025 Revision: Part I. Allergy. 2026;81(4):954â976. DOI: 10.1111/all.70131
- Carrie S, et al. Clinical effectiveness of septoplasty versus medical management for nasal airways obstruction: multicentre, open-label, randomised controlled trial. BMJ. 2023;383:e075445. DOI: 10.1136/bmj-2023-075445
Verified Drug References â MedEx Bangladesh
- Biltin 20 mg â Bilastine
- Lumona 10 mg â Montelukast Sodium
- Rynex 0.05% Nasal Drop â Oxymetazoline
Author: Md.Rafiqul Islam Lipu
Date: Wednesday, 28 October 2026
Time: 01:06 PM (Bangladesh Standard Time, UTC+06:00)
Publication Series: LIPU MED â Clinical Case Review
Case Reference: TC(1449).(12). ENT Department Case No (103)
Clinical status: Evidence-based educational working assessment; definitive diagnosis requires direct patient evaluation.